JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 38 No. 10 1636-1639
© 1997 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abdel-Dayem, H. M.
Right arrow Articles by Radin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdel-Dayem, H. M.
Right arrow Articles by Radin, A.

Demonstration of Rectosigmoid Fistula Dynamic Scintigraphic Peritoneography

Hussein M. Abdel-Dayem, Stephane Lubicz and Arthur Radin

Nuclear Medicine Section and Section of Medical Oncology
Departments of Nuclear Medicine, Obstetrics and Gynecology and Medicine, New York Medical College, Valhalla
St. Vincent's Hospital and Medical Center, New York, New York

Correspondence: For correspondence or reprints contact: Hussein M. Abdel-Dayem, MD, St. Vincent's Hospital and Medical Center, Nuclear Medicine Service, 153 West 11th St., New York, NY 10011.

ABSTRACT

Intraperitoneal installation of chemotherapy through a Mediport implanted subcutaneously in the abdominal wall is used currently for treatment of peritoneal metastases from ovarian, gastric and colonie carcinoma. There is a variable incidence of complications due to the procedure reported in the literature. The main predisposing factor for these complications is the in homogeneous distribution of the chemotherapeutic drugs within the peritoneal cavity. We report an unusual case of a rectosigmoid fistula that developed 6 wk following the insertion of a Bardport subcutaneously in the abdominal wall for intraperitoneal therapy. The fistula was clearly demonstrated by dynamic scintigraphic peritoneography. This is a new modification of scintigraphic peritoneography as practiced routinely. We endorse the previous recommendation that scintigraphic peritoneography be apeutic drug or radiopharmaceutical to ensure the homogeneous distribution of the drugs and to prevent complications.

Key Words: intraperitonealchemotherapy • peritoneography • ovarian cancer • colon cancer • gastric cancer






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1997 by the Society of Nuclear Medicine.